Insulin analogs with improved pharmacokinetic profiles
- 22 January 1999
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 35 (2-3), 307-335
- https://doi.org/10.1016/s0169-409x(98)00079-9
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study GroupArchives of Internal Medicine, 1997
- Prolonged Efficacy of Short Acting Insulin Lispro in Combination with Human Ultralente in Insulin-Dependent Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 1997
- Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulinDiabetes, 1996
- Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell FunctionDiabetes Care, 1995
- Preparation of an Insulin with Improved Pharmacokinetics Relative to Human Insulin through Consideration of Structural Homology with Insulin-Like Growth Factor IHormone Research, 1994
- Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28AspDiabetic Medicine, 1993
- Role of B13 Glu in insulin assembly: The hexamer structure of recombinant mutant (B13 Glu → Gln) insulinJournal of Molecular Biology, 1992
- In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical UseDiabetic Medicine, 1991
- Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetesThe Lancet, 1990
- Variation in125i-insulin absorption and blood glucose concentrationDiabetologia, 1979